Home » Stocks » SAGE

Sage Therapeutics, Inc. (SAGE)

Stock Price: $72.64 USD -1.45 (-1.96%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $71.50 -1.14 (-1.57%) Dec 1, 7:50 PM

Stock Price Chart

Key Info

Market Cap 3.78B
Revenue (ttm) 6.97M
Net Income (ttm) -537.48M
Shares Out 52.04M
EPS (ttm) -10.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $72.64
Previous Close $74.09
Change ($) -1.45
Change (%) -1.96%
Day's Open 72.70
Day's Range 71.56 - 73.98
Day's Volume 942,710
52-Week Range 25.95 - 149.21

More Stats

Market Cap 3.78B
Enterprise Value 3.14B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 52.04M
Float n/a
EPS (basic) -10.35
EPS (diluted) -10.35
FCF / Share -8.93
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.35M
Short Ratio 9.08
Short % of Float n/a
Beta 2.38
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 542.09
PB Ratio 5.98
Revenue 6.97M
Operating Income -552.39M
Net Income -537.48M
Free Cash Flow -464.14M
Net Cash 641.22M
Net Cash / Share 12.32
Gross Margin -5,195.68%
Operating Margin -7,920.66%
Profit Margin -7,706.80%
FCF Margin -6,655.22%
ROA -33.76%
ROE -61.83%
ROIC -81.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (21)

Buy 13
Overweight 1
Hold 7
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(34.43% upside)
Current: $72.64
Target: 97.65
*Average 12-month price target from 20 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-92.39%-------
Gross Profit6.4790.27------
Operating Income-708-393-273-160-94.65-33.81-18.28-9.63
Net Income-680-373-270-159-94.50-33.81-18.28-9.63
Shares Outstanding50.8346.1238.1133.4927.7821.571.491.12
Earnings Per Share-13.38-8.08-7.09-4.75-3.40-1.67-12.26-8.62
Operating Cash Flow-529-261-219-119-70.68-27.04-17.52-8.93
Capital Expenditures-5.75-2.86-1.36-1.42-0.20-0.13--0.11
Free Cash Flow-534-264-221-120-70.88-27.17-17.52-9.04
Cash & Equivalents1,0119255203981871288.112.84
Total Debt37.09-------
Net Cash / Debt9749255203981871288.112.84
Book Value945863475369174122-31.54-13.39
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sage Therapeutics, Inc.
Country United States
Employees 675
CEO Jeffrey M. Jonas

Stock Information

Ticker Symbol SAGE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SAGE
IPO Date July 18, 2014


Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Company for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.